0R15 9080.0 -2.7837% 0R1E 9565.0 5.7373% 0M69 None None% 0R2V 233.75 12.1103% 0QYR 1560.0 -0.7634% 0QYP 409.5 0.0% 0RUK None None% 0RYA 1576.0 1.2203% 0RIH 190.65 0.0% 0RIH 190.3 -0.1836% 0R1O 218.55 9948.2759% 0R1O None None% 0QFP 10717.21 112.6431% 0M2Z 295.8502 1.1713% 0VSO 32.02 -10.0688% 0R1I None None% 0QZI 595.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 226.55 0.1373%
Last update at 2025-01-14T18:59:00Z
Is ResMed Stock a Smart Addition to Your Portfolio Right Now?
Thu 17 Oct 24, 02:19 PMHaemonetics Corp (HAE) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges
Wed 09 Oct 24, 09:28 PMRobust Plasma Sales, New Innovations Aid Haemonetics Stock
Tue 08 Oct 24, 05:54 PMHaemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024
Thu 03 Oct 24, 08:05 PMHere's Why You Should Add HAE Stock in Your Portfolio Now
Thu 26 Sep 24, 12:47 PM4 Medical Product Stocks to Buy From a Prospective Industry
Tue 24 Sep 24, 12:06 PMTaking A Look At Haemonetics Corporation's (NYSE:HAE) ROE
Tue 24 Sep 24, 11:45 AMIs Haemonetics Corporation (HAE) an Undervalued Healthcare Stock to Buy in 2025
Fri 20 Sep 24, 04:54 AM| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Income before tax | 141.40M | 63.63M | 72.91M | 87.15M | 73.63M |
| Minority interest | - | - | - | - | - |
| Net income | 115.40M | 43.38M | 79.47M | 76.53M | 55.02M |
| Selling general administrative | 376.68M | 339.56M | 274.19M | 284.00M | 284.65M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 615.10M | 505.50M | 397.84M | 484.51M | 417.54M |
| Reconciled depreciation | 93.31M | 97.75M | 84.29M | 110.29M | 109.42M |
| Ebit | 156.03M | 80.75M | 57.96M | 153.95M | 83.55M |
| Ebitda | 249.34M | 169.47M | 142.25M | 264.24M | 192.96M |
| Depreciation and amortization | 93.31M | 88.72M | 84.29M | 110.29M | 109.42M |
| Non operating income net other | -14.63000M | -17.12100M | -16.83400M | -16.19900M | -9.91200M |
| Operating income | 156.03M | 80.75M | 57.96M | 153.95M | 83.55M |
| Other operating expenses | 459.06M | 921.47M | 812.50M | 834.53M | 884.03M |
| Interest expense | 14.63M | 17.12M | 16.83M | 16.20M | 9.91M |
| Tax provision | 26.00M | 20.25M | -6.55600M | 10.63M | 18.61M |
| Interest income | 14.63M | 17.12M | 16.83M | 16.20M | 9.91M |
| Net interest income | -14.63000M | -17.12100M | -16.83400M | -16.19900M | -9.91200M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | 0.58M | 1.03M | 50.60M | - |
| Other items | - | - | - | - | - |
| Income tax expense | 26.00M | 20.25M | -6.55600M | 10.63M | 18.61M |
| Total revenue | 1168.66M | 993.20M | 870.46M | 988.48M | 967.58M |
| Total operating expenses | 459.06M | 433.78M | 339.88M | 330.56M | 333.99M |
| Cost of revenue | 553.56M | 487.69M | 472.62M | 503.97M | 550.04M |
| Total other income expense net | -14.63000M | -17.12100M | 14.95M | -66.79800M | -9.91200M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 115.40M | 43.38M | 79.47M | 76.53M | 55.02M |
| Net income applicable to common shares | 115.40M | 43.38M | 79.47M | 76.53M | 55.02M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Total assets | 1934.83M | 1859.73M | 1819.92M | 1267.11M | 1274.77M |
| Intangible assets | 275.77M | 310.26M | 365.48M | 133.11M | 127.69M |
| Earning assets | - | - | - | - | - |
| Other current assets | 46.73M | 44.13M | 51.07M | 30.84M | 27.41M |
| Total liab | 1116.83M | 1110.31M | 1088.25M | 680.00M | 606.90M |
| Total stockholder equity | 818.00M | 749.42M | 731.67M | 587.11M | 667.87M |
| Deferred long term liab | 36.20M | 28.73M | 43.83M | 10.56M | 19.91M |
| Other current liab | 145.89M | 137.92M | 159.91M | 127.75M | 117.45M |
| Common stock | 0.50M | 0.51M | 0.51M | 0.50M | 0.51M |
| Capital stock | 0.50M | 0.51M | 0.51M | 0.50M | 0.51M |
| Retained earnings | 253.17M | 202.39M | 157.98M | 78.51M | 161.42M |
| Other liab | - | 108.60M | 76.91M | 38.18M | 48.69M |
| Good will | 466.23M | 467.29M | 466.44M | 210.65M | 210.82M |
| Other assets | 58.80M | 67.67M | 17.04M | 14.08M | 16.16M |
| Cash | 284.47M | 259.50M | 192.31M | 137.31M | 169.35M |
| Cash and equivalents | 284.47M | 259.50M | 192.31M | 137.31M | 169.35M |
| Total current liabilities | 251.82M | 442.27M | 253.50M | 284.30M | 235.76M |
| Current deferred revenue | 30.21M | 31.83M | 26.27M | 28.84M | 27.28M |
| Net debt | 481.42M | 514.09M | 515.30M | 245.18M | 180.77M |
| Short term debt | 11.78M | 214.15M | 17.02M | 76.98M | 27.67M |
| Short long term debt | 11.78M | 214.15M | 17.02M | 76.98M | 27.67M |
| Short long term debt total | 765.89M | 773.59M | 707.61M | 382.49M | 350.12M |
| Other stockholder equity | 594.71M | 572.48M | 602.73M | 553.23M | 536.32M |
| Property plant equipment | 310.88M | 258.48M | 277.42M | 253.40M | 343.98M |
| Total current assets | 769.72M | 756.03M | 693.55M | 603.64M | 576.12M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 76.00M | -28.12400M | -100.25700M | 243.35M | 329.36M |
| Short term investments | - | - | - | - | - |
| Net receivables | 179.14M | 159.38M | 127.56M | 165.21M | 185.03M |
| Long term debt | 754.10M | 559.44M | 690.59M | 305.51M | 322.45M |
| Inventory | 259.38M | 293.03M | 322.61M | 270.28M | 194.34M |
| Accounts payable | 63.93M | 58.37M | 50.29M | 50.73M | 63.36M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -30.38100M | -25.95400M | -29.54700M | -45.13500M | -30.38000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 0.50M | 0.51M | 0.51M | 0.50M | 0.51M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 253.17M | 202.39M | 157.98M | 78.51M | 161.42M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 106.97M | 63.20M | 76.89M | 66.31M | 16.16M |
| Deferred long term asset charges | - | - | - | - | 4.36M |
| Non current assets total | 1165.10M | 1103.70M | 1126.38M | 663.47M | 698.65M |
| Capital lease obligations | - | 7.20M | 70.67M | 59.32M | - |
| Long term debt total | 754.10M | 559.44M | 690.59M | 305.51M | 322.45M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Investments | -143.78800M | -86.34500M | -425.44200M | -57.17600M | -116.14800M |
| Change to liabilities | 39.82M | 7.64M | -56.42200M | -17.30800M | 17.74M |
| Total cashflows from investing activities | -143.78800M | -86.34500M | -425.44200M | -57.17600M | -116.14800M |
| Net borrowings | 269.26M | -17.50000M | 370.73M | 31.88M | 95.93M |
| Total cash from financing activities | -100.36400M | -15.74900M | 367.45M | -131.20800M | -50.62800M |
| Change to operating activities | - | -4.51000M | -4.65000M | -2.87600M | 0.49M |
| Net income | 115.40M | 43.38M | 79.47M | 76.53M | 55.02M |
| Change in cash | 24.97M | 67.19M | 54.99M | -32.04000M | -10.81800M |
| Begin period cash flow | 259.50M | 192.31M | 137.31M | 169.35M | 180.17M |
| End period cash flow | 284.47M | 259.50M | 192.31M | 137.31M | 169.35M |
| Total cash from operating activities | 273.06M | 172.26M | 108.81M | 158.22M | 159.28M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 93.31M | 97.75M | 84.29M | 110.29M | 109.42M |
| Other cashflows from investing activities | -0.39200M | 10.16M | -388.40200M | -8.41800M | 2.81M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 30.75M | 24.31M | -38.90900M | -84.72100M | -39.32200M |
| Change to account receivables | -24.42100M | -34.97400M | 44.12M | 18.86M | -38.06400M |
| Sale purchase of stock | -75.00000M | 6.55M | 10.23M | -175.00000M | -160.00000M |
| Other cashflows from financing activities | -15.73900M | 1.75M | 449.33M | 56.92M | 376.23M |
| Change to netincome | 36.21M | 46.32M | 4.73M | 64.05M | 57.59M |
| Capital expenditures | 110.19M | 96.51M | 37.04M | 48.76M | 118.96M |
| Change receivables | -24.42100M | -34.97400M | 44.12M | 18.86M | -38.06400M |
| Cash flows other operating | -19.98200M | -22.61600M | -33.42400M | -9.47900M | -3.10000M |
| Exchange rate changes | - | - | - | - | -3.32300M |
| Cash and cash equivalents changes | 28.91M | 70.17M | 50.81M | -30.16700M | -10.81800M |
| Change in working capital | 25.50M | -15.17700M | -59.68200M | -84.56200M | -62.75000M |
| Stock based compensation | 25.58M | 24.36M | 25.52M | 20.45M | 17.19M |
| Other non cash items | 8.48M | 16.95M | -0.91900M | 42.47M | 27.05M |
| Free cash flow | 162.87M | 75.75M | 71.77M | 109.46M | 40.32M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HAE Haemonetics Corporation |
0.59 0.74% | 80.00 | 35.49 | 21.05 | 3.62 | 5.02 | 3.95 | 18.76 |
| ISRG Intuitive Surgical Inc |
0.88 0.16% | 540.63 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOY Essilor International SA |
0.76 0.64% | 120.35 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
| ESLOF EssilorLuxottica Société anonyme |
- -% | 239.18 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
| BDX Becton Dickinson and Company |
-1.34 0.57% | 234.85 | 37.72 | 15.92 | 3.25 | 2.49 | 4.08 | 17.10 |
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
125 Summer Street, Boston, MA, United States, 02110
| Name | Title | Year Born |
|---|---|---|
| Mr. Christopher A. Simon | CEO, Pres & Director | 1964 |
| Mr. Josep Lluis Llorens | Exec. VP of Global Manufacturing & Supply Chain | 1963 |
| Mr. Stewart W. Strong | Pres of Global Hospital | 1967 |
| Mr. James C. D'Arecca CPA | CFO, Exec. VP & Financial Officer | 1971 |
| Ms. Farris Maryanne Maunsell | VP, Chief Accounting Officer & Principal Accounting Officer | 1975 |
| Ms. Anila Lingamneni | Exec. VP & CTO | 1968 |
| Ms. Olga Guyette | Director of Investor Relations | NA |
| Carla Burigatto | VP of Communications | NA |
| Mr. Francis Tan | Sr. VP of Corp. Devel. & Planning | NA |
| Ms. Laurie A. Miller | Sr. VP & Chief HR Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...